Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with imiquimod in indu...

Full description

Bibliographic Details
Main Authors: Hansje-Eva Teulings, Esther P. M. Tjin, Karina J. Willemsen, Stephanie van der Kleij, Sylvia ter Meulen, E. Helen Kemp, Gabrielle Krebbers, Carel J. M. van Noesel, Cornelis L. M. C. Franken, Jan W. Drijfhout, Cornelis J. M. Melief, Ludmila Nieuweboer-Krobotova, Omgo E. Nieweg, Jos A. van der Hage, J. P. Wietze van der Veen, Germaine N. Relyveld, Rosalie M. Luiten
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
melanoma
immunotherapy
vitiligo
cutaneous metastases
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1419113

Internet

http://dx.doi.org/10.1080/2162402X.2017.1419113

Similar Items